| ²é¿´: 2038 | »Ø¸´: 7 | ||||
¹Å¿É¤×ÈÙÓþ°æÖ÷ (ÎÄ̳¾«Ó¢)
|
[½»Á÷]
FDAÑÓ³ÙÅú×¼¸ðÀ¼ËØÊ·¿ËGLP-1Ò©Îï°¢±ØÂ³ëÄ ÒÑÓÐ4È˲ÎÓë
|
|
ÐÅÏ¢À´Ô´£ºhttp://www.reuters.com/article/2 ... USBRE9710Q620130802 Ô±êÌ⣺¸ðÀ¼ËØÊ·¿ËÌÇÄò²¡Ò©ÃæÁÙU.S.µÄÑÓ³ÙÅú×¼ £¨Â·Í¸É磩-Ó¢¹ú×î´óÖÆÒ©ÉÌÖÜÎ峯£¬U.S.¼à¹Ü²¿ÃÅÒѾ½«¸ðÀ¼ËØÊ·¿ËʵÑéÐÔÌÇÄò²¡Ò©Îï°¢±ØÂ³ëĵÄÅú×¼¾ö¶¨ÍƳÙ3¸öÔÂÖÁ2014Äê4ÔÂ15ÈÕ¡£ ¸ÃÒ©ÔÚÅ·ÖÞ°´¼Æ»®½øÐÐÉêÇë¡£¸ÃÒ©ÓÃÓÚ2ÐÍÌÇÄò²¡£¬Ã¿ÖÜÖÎÁÆÒ»´Î£¬ÓëŵºÍŵµÂÀûÀ³ëÄ£¬°ÙʱÃÀÊ©¹ó±¦ºÍ°¢Ë¹Àû¿µµÄByetta¼° BydureonÊôÓÚͬÀà×¢ÉäÐÍÈËÒÈÉýѪÌÇËØÑùëÄ-1£¨GLP-1£©Ò©Îï¡£ »ùÓÚÁÙ´²ÊÔÑé½á¹û±¨µÀ£¬ÒµÄÚ·ÖÎöʦ»³Òɰ¢±ØÂ³ëÄÔÚÓµ¼·µÄÊг¡ÄÜ·Öµ½¶àÉÙ·Ý¶î£¬ÌØ±ðÊÇÃæÁÙͬÏßÐÂDZÔÚ¶ÔÊÖÀñÀ´µÄ¶ÈÀ³ëÄ¡£ GLP-1ÀàÒ©ÎïÔÚÁÙ´²ÉϵÄÊÜÏÞÓÚÈËÌå×ÔÉí²úÉúµÄGLP-1 Ò×±»ÌåÄڵĶþëÄ»ùëÄø¢ô(DPP-¢ô)½µ½â,ÆäѪ½¬°ëË¥ÆÚ²»×ã2·ÖÖÓ,±ØÐë³ÖÐø¾²ÂöµÎ×¢»ò³ÖÐøÆ¤ÏÂ×¢Éä²ÅÄܲúÉúÁÆÐ§,´ó´óÏÞÖÆËüµÄÁÙ´²Ó¦Óᣰ¢±ØÂ³ëÄΪ¶þëÄ»ùëÄøÞ׿¹ÒȸßѪÌÇËØÑùëĶþ¾ÛÌåÈËѪÇåµ°°×ÈÚºÏÎ°ëË¥ÆÚ4-7Ì죬ÔÚ°ëË¥ÆÚÉϱÈÒѾÉÏÊеÄGLP-1ÀàÒ©Îï°¬ÈûÄÇëĺÍÀûÀ³ëÄÓÐÓÅÊÆ¡£¸ÃÒ©ÔÚÃÀÈÕ¹²½øÐÐ22ÏîÁÙ´²Ñо¿°üÀ¨ÓÐЧÐÔ°²È«ÐÔÒÔ¼°Ò©ÎïÏ໥×÷ÓõÈhttp://clinicaltrials.gov/ct2/re ... lutide&pg=1 £¬ÍƳÙÅú×¼µÄÔÒòÊÇ£¿ÓиßÈ˽â´ð·ñ£¿ GlaxoSmithKline diabetes drug faces U.S. approval delay (Reuters) - U.S. regulators have pushed back an approval decision on GlaxoSmithKline's experimental diabetes drug albiglutide by three months until April 15, 2014, Britain's biggest drugmaker said on Friday. A separate filing for the drug in Europe is progressing on schedule. The once-weekly treatment for type 2 diabetes belongs to the same class of injectable GLP-1 drugs as Victoza, from Novo Nordisk, and Byetta and Bydureon, from Bristol-Myers Squibb and AstraZeneca. Based on reported clinical trial results, industry analysts have questioned how well albiglutide will fare in a crowded market - especially with a promising new rival in the pipeline in the form of Eli Lilly's dulaglutide. (Reporting by Ben Hirschler; Editing by Keith Weir) |
» ÊÕ¼±¾ÌûµÄÌÔÌûר¼ÍƼö
ÐÂÒ©¶¯Ì¬ |
» ±¾ÌûÒÑ»ñµÃµÄºì»¨£¨×îÐÂ10¶ä£©
» ²ÂÄãϲ»¶
ҩѧר˶µ÷¼Á
ÒѾÓÐ2È˻ظ´
ҩѧѧ˶326Çóµ÷¼Á
ÒѾÓÐ1È˻ظ´
Ò©ÀíѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ119È˻ظ´
105500ҩѧµ÷¼Á£¬Ò»Ö¾Ô¸¶¥9£¬Ö÷³ÖÊ¡¼¶´ó´´£¬ÊµÑéÐÍSCI¶þ×÷£¬ËÄÁù¼¶Òѹý£¬Ë«¹ú½±
ÒѾÓÐ6È˻ظ´
ҩѧר˶µ÷¼Á
ÒѾÓÐ0È˻ظ´
publcifµÄʹÓÃ
ÒѾÓÐ0È˻ظ´
Ò»Ö¾Ô¸ËÕÖÝ´óѧ ÉúÎï¼¼ÊõÓ빤³Ì£¨086001£© ³õÊÔ323·Ö£¬Çóµ÷¼Á
ÒѾÓÐ0È˻ظ´
ÈýÄêʵÑéÊÒ¹¤×÷¾Àú£¬Ò»Ö¾Ô¸»ªÖÐũҵ´óѧ΢ÉúÎ×Ü·Ö288Çóµ÷¼Á
ÒѾÓÐ0È˻ظ´
Çóµ÷¼Á
ÒѾÓÐ2È˻ظ´
»á¼Æ×¨Ë¶Çóµ÷¼Á
ÒѾÓÐ0È˻ظ´
ÐÂ¼ÓÆÂ¹úÁ¢´óѧҩѧϵ»¯Ñ§ÉúÎïѧ¿ÎÌâ×éÕÐPhD
ÒѾÓÐ12È˻ظ´

ºîå·Ë§
ľ³æ (ÕýʽдÊÖ)
- Ó¦Öú: 11 (СѧÉú)
- ½ð±Ò: 2339
- ºì»¨: 7
- Ìû×Ó: 764
- ÔÚÏß: 48.4Сʱ
- ³æºÅ: 1660205
- ×¢²á: 2012-03-03
- רҵ: ÕþÖÎѧÀíÂÛ
2Â¥2013-08-05 02:32:24
ÓÆÓÆÂäÒ¶
½ð³æ (ÕýʽдÊÖ)
- Ó¦Öú: 72 (³õÖÐÉú)
- ½ð±Ò: 942.8
- ºì»¨: 4
- Ìû×Ó: 345
- ÔÚÏß: 137.7Сʱ
- ³æºÅ: 1533170
- ×¢²á: 2011-12-11
- ÐÔ±ð: GG
- רҵ: ÓлúºÏ³É

3Â¥2013-08-05 18:15:01
amisking
ÈÙÓþ°æÖ÷ (ÎÄ̳¾«Ó¢)
- Ó¦Öú: 45 (СѧÉú)
- ¹ó±ö: 28.304
- ½ð±Ò: 51353.9
- É¢½ð: 3080
- ºì»¨: 78
- ɳ·¢: 17
- Ìû×Ó: 13022
- ÔÚÏß: 839Сʱ
- ³æºÅ: 514230
- ×¢²á: 2008-02-28
- ÐÔ±ð: GG
- רҵ: ΢ÉúÎï×ÊÔ´Óë·ÖÀàѧ
- ¹ÜϽ: ·Ö×ÓÉúÎï

4Â¥2013-08-05 18:34:06
¹Å¿É¤×
ÈÙÓþ°æÖ÷ (ÎÄ̳¾«Ó¢)
- Ó¦Öú: 91 (³õÖÐÉú)
- ¹ó±ö: 16.835
- ½ð±Ò: 19237.1
- É¢½ð: 40372
- ºì»¨: 275
- ɳ·¢: 183
- Ìû×Ó: 25406
- ÔÚÏß: 1082.3Сʱ
- ³æºÅ: 1034379
- ×¢²á: 2010-06-02
- ÐÔ±ð: GG
- רҵ: Ò©ÎïÉè¼ÆÓëÒ©ÎïÐÅÏ¢
- ¹ÜϽ: µ¼Ê¦ÕÐÉú

5Â¥2013-08-05 18:48:16
ÓÆÓÆÂäÒ¶
½ð³æ (ÕýʽдÊÖ)
- Ó¦Öú: 72 (³õÖÐÉú)
- ½ð±Ò: 942.8
- ºì»¨: 4
- Ìû×Ó: 345
- ÔÚÏß: 137.7Сʱ
- ³æºÅ: 1533170
- ×¢²á: 2011-12-11
- ÐÔ±ð: GG
- רҵ: ÓлúºÏ³É

6Â¥2013-08-05 20:45:00
ÌÕÈËÑà
гæ (³õÈëÎÄ̳)
- Ó¦Öú: 1 (Ó×¶ùÔ°)
- ½ð±Ò: 33.1
- Ìû×Ó: 30
- ÔÚÏß: 5.4Сʱ
- ³æºÅ: 2008970
- ×¢²á: 2012-09-17
- ÐÔ±ð: GG
- רҵ: ÓлúºÏ³É

7Â¥2013-08-20 08:43:36
ÌÕÈËÑà
гæ (³õÈëÎÄ̳)
- Ó¦Öú: 1 (Ó×¶ùÔ°)
- ½ð±Ò: 33.1
- Ìû×Ó: 30
- ÔÚÏß: 5.4Сʱ
- ³æºÅ: 2008970
- ×¢²á: 2012-09-17
- ÐÔ±ð: GG
- רҵ: ÓлúºÏ³É

8Â¥2013-08-20 08:45:45













»Ø¸´´ËÂ¥
ÌÕÈËÑà